Eli Lilly and Company $LLY Shares Acquired by Fort Washington Investment Advisors Inc. OH

Fort Washington Investment Advisors Inc. OH grew its stake in Eli Lilly and Company (NYSE:LLY) by 4.5% in the first quarter, HoldingsChannel reports. The institutional investor owned 52,225 shares of the company’s stock after buying an additional 2,257 shares during the period. Fort Washington Investment Advisors Inc. OH’s holdings in Eli Lilly and Company were worth $48,035,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in LLY. Maryland Capital Advisors Inc. acquired a new position in shares of Eli Lilly and Company in the fourth quarter valued at about $25,000. Osbon Capital Management LLC acquired a new stake in shares of Eli Lilly and Company during the fourth quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of Eli Lilly and Company by 84.2% during the third quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after purchasing an additional 16 shares during the period. Basso Capital Management L.P. purchased a new stake in Eli Lilly and Company in the fourth quarter valued at approximately $30,000. Finally, 10Elms LLP boosted its position in Eli Lilly and Company by 33.3% in the third quarter. 10Elms LLP now owns 40 shares of the company’s stock valued at $31,000 after buying an additional 10 shares during the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.1%

Shares of LLY stock opened at $1,206.51 on Monday. The stock has a 50 day moving average of $1,036.28 and a 200 day moving average of $1,021.13. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The stock has a market cap of $1.14 trillion, a P/E ratio of 42.86, a P/E/G ratio of 1.32 and a beta of 0.53. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $1,215.76.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion during the quarter, compared to the consensus estimate of $17.82 billion. During the same period in the previous year, the company posted $3.34 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. As a group, sell-side analysts expect that Eli Lilly and Company will post 35.8 EPS for the current year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is currently 24.58%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the stock. Sanford C. Bernstein reissued an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $1,285.00 price objective on shares of Eli Lilly and Company in a report on Friday, March 6th. BMO Capital Markets reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Monday, June 15th. Royal Bank Of Canada reissued an “outperform” rating on shares of Eli Lilly and Company in a report on Thursday, May 21st. Finally, Leerink Partners boosted their target price on shares of Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a research report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $1,235.07.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.